Biotricity (BTCY) 10-Q 14 Nov 23 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	001-40761
Entity Registrant Name	BIOTRICITY INC.
Entity Central Index Key	0001630113
Entity Tax Identification Number	30-0983531
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	203 Redwood Shores Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	(650)
Local Phone Number	832-1626
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BTCY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,768,650

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Mar. 31, 2023
CURRENT ASSETS
Cash	$ 1,199,725	$ 570,460
Accounts receivable, net	1,610,074	1,224,137
Inventories [Note 3]	2,128,196	2,337,006
Deposits and other receivables	240,211	588,599
Total current assets	5,178,206	4,720,202
Deposits [Note 10]	85,000	85,000
Long-term accounts receivable	132,930	96,344
Property and equipment [Note 12]	18,529	21,506
Operating right of use assets [Note 10]	1,409,172	1,587,492
TOTAL ASSETS	6,823,837	6,510,544
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	6,658,626	5,042,476
Convertible promissory notes and short term loans [Note 5]	6,717,731	4,774,468
Term loan, current [Note 6]	1,200,000
Derivative liabilities [Note 8]	2,883,978	1,008,216
Operating lease obligations, current [Note 10]	364,028	335,608
Total current liabilities	17,824,363	11,160,768
Federally guaranteed loans [Note 7]	870,800	870,800
Term loan [Note 6]	11,081,475	12,178,809
Derivative liabilities [Note 8]	1,351,448	759,065
Operating lease obligations [Note 10]	1,167,203	1,386,487
TOTAL LIABILITIES	32,295,289	26,355,929
STOCKHOLDERS’ DEFICIENCY
Common stock, $0.001 par value, 125,000,000 shares authorized as of September 30, 2023 and March 31, 2023. Issued and outstanding common shares: 8,565,795 and 8,508,052 as of September 30, 2023 and March 31, 2023, respectively, and exchangeable shares of 244,453 outstanding at September 30, 2023 and March 31, 2023 [Note 9]	8,811	8,753
Shares to be issued, 3,955 shares of common stock as of September 30, 2023 and March 31, 2023 [Note 9]	24,999	24,999
Additional paid-in-capital	93,338,220	92,844,478
Accumulated other comprehensive loss	(47,387)	(152,797)
Accumulated deficit	(120,053,686)	(112,570,825)
TOTAL STOCKHOLDERS’ DEFICIENCY	(26,729,036)	(19,845,385)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY	6,823,837	6,510,544
SerieB convertible redeemable preferre stock [Member]
Mezzanine Equity
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 and no shares authorized as of September 30, 2023 and March 31, 2023, respectively, 220 and no shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively [Note 9]	1,257,584
Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock,value	1	1
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock,value	$ 6	$ 6

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Mar. 31, 2023
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	8,565,795	8,508,052
Common stock, shares outstanding	8,565,795	8,508,052
Common stock, other shares outstanding	244,453	244,453
Common stock shares to be issued	3,955	3,955
SerieB convertible redeemable preferre stock [Member]
Series B converible redeemable preferred stock. par value	$ 0.001	$ 0.001
Series B converible redeemable preferred stock, authorized	600	0
Series B converible redeemable preferred stock, shares issued	220	0
Series B converible redeemable preferred stock, shares outstanding	220	0
Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	9,979,400	9,980,000
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	6,304	6,304
Preferred stock, shares outstanding	6,304	6,304

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
REVENUE	$ 2,891,297	$ 2,381,389	$ 5,912,062	$ 4,437,441
Cost of Revenue	892,019	1,101,152	1,996,080	1,932,075
NET REVENUE	1,999,278	1,280,237	3,915,982	2,505,366
EXPENSES
Selling. general and administrative expenses	3,487,331	4,480,310	7,007,546	8,972,924
Research and development expenses	697,620	828,914	1,410,595	1,650,090
TOTAL OPERATING EXPENSES	4,184,951	5,309,224	8,418,141	10,623,014
LOSS FROM OPERATIONS	(2,185,673)	(4,028,987)	(4,502,159)	(8,117,648)
Interest expense [Note 5, 6 and 9]	(753,268)	(403,551)	(1,413,780)	(791,940)
Accretion and amortization expenses [Note 5,6]	(596,420)	(50,839)	(1,153,639)	(100,909)
Change in fair value of derivative liabilities [Note 8]	(18,783)	(172,042)	82,669	(370,266)
Gain (loss) upon convertible promissory notes conversion and redemption	6,684	(40,020)	13,132	(90,928)
Other (expense) income/	(143,380)	2,891	(129,945)	2,891
NET LOSS BEFORE INCOME TAXES	(3,690,840)	(4,692,548)	(7,103,722)	(9,468,800)
Income taxes
NET LOSS BEFORE DIVIDENDS	(3,690,840)	(4,692,548)	(7,103,722)	(9,468,800)
Adjustment: Preferred Stock Dividends	(190,442)	(211,819)	(379,139)	(459,956)
NET LOSS ATTRIBUTABLE TO COMMON STOCKLHOLDERS	(3,881,282)	(4,904,367)	(7,482,861)	(9,928,756)
Translation adjustment	281,240	465,517	105,410	698,521
COMPREHENSIVE LOSS	$ (3,600,042)	$ (4,438,850)	$ (7,377,451)	$ (9,230,235)
LOSS PER SHARE, BASIC	$ (0.441)	$ (0.567)	$ (0.853)	$ (1.153)
LOSS PER SHARE, DILUTED	$ (0.441)	$ (0.567)	$ (0.853)	$ (1.153)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	8,795,742	8,642,937	8,774,242	8,608,447
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	8,795,742	8,642,937	8,774,242	8,608,447

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023
Balance	$ (23,411,614)	$ (6,560,418)	$ (2,144,736)	$ (19,845,385)	$ (2,144,736)	$ (2,144,736)
Issuance of common stock	119,285			119,285
Stock based compensation - ESOP [Note 9]	163,335	153,338		374,515	302,528
Translation adjustment	281,240	465,517		105,410	698,521
Net loss before dividends for the period	(3,690,840)	(4,692,548)		(7,103,722)	(9,468,800)
Preferred stock dividends	(190,442)	(211,819)		(379,139)	(459,956)
Preferred stock purchased back via cash		(60,619)			(346,046)
Conversion of convertible notes into common shares [Note 9]		175,294			632,320
Issuance of shares for services [Note 9]		30,287			37,787
Exercise of warrants for cash [Note 9]					(30,000)
Exercise of warrants for cash [Note 9], shares		47,300
Issuance of warrants for services [Note 9]		$ 77,332			154,746
Balance	(26,729,036)	(10,623,636)	(6,560,418)	(26,729,036)	(10,623,636)	(19,845,385)
Preferred Stock [Member]
Balance	$ 7	$ 8	$ 8	$ 7	$ 8	$ 8
Balance, shares	6,305	6,872	7,201	6,305	7,201	7,201
Issuance of common stock
Stock based compensation - ESOP [Note 9]
Translation adjustment
Net loss before dividends for the period
Preferred stock dividends
Preferred stock purchased back via cash
Preferred stock purchased back via cash, shares		(70)			(399)
Conversion of convertible notes into common shares [Note 9]
Issuance of shares for services [Note 9]
Exercise of warrants for cash [Note 9]
Issuance of warrants for services [Note 9]
Balance	$ 7	$ 8	$ 8	$ 7	$ 8	$ 7
Balance, shares	6,305	6,802	6,872	6,305	6,802	6,305
Common Stock [Member]
Balance	$ 8,753	$ 8,614	$ 8,546	$ 8,753	$ 8,546	$ 8,546
Balance, shares	8,752,505	8,614,355	8,546,261	8,752,505	8,546,261	8,546,261
Issuance of common stock	$ 58			$ 58
Issuance of common stock, shares	57,743			57,743
Stock based compensation - ESOP [Note 9]
Translation adjustment
Net loss before dividends for the period
Preferred stock dividends
Preferred stock purchased back via cash
Conversion of convertible notes into common shares [Note 9]		$ 20			$ 87
Conversion of convertible notes into common shares, shares		19,604			87,003
Issuance of shares for services [Note 9]		$ 4			$ 5
Issuance of shares for services [Note 9], shares		3,796			4,491
Exercise of warrants for cash [Note 9]		$ 12			$ 12
Exercise of warrants for cash [Note 9], shares		11,966			11,966
Issuance of warrants for services [Note 9]
Balance	$ 8,811	$ 8,650	$ 8,614	$ 8,811	$ 8,650	$ 8,753
Balance, shares	8,810,248	8,649,721	8,614,355	8,810,248	8,649,721	8,752,505
Shares to be Issued [Member]
Balance	$ 24,999	$ 72,299	$ 102,299	$ 24,999	$ 102,299	$ 102,299
Balance, shares	3,955	15,921	20,638	3,955	20,638	20,638
Issuance of common stock
Stock based compensation - ESOP [Note 9]
Translation adjustment
Net loss before dividends for the period
Preferred stock dividends
Preferred stock purchased back via cash
Conversion of convertible notes into common shares [Note 9]
Issuance of shares for services [Note 9]
Exercise of warrants for cash [Note 9]		$ (47,300)			$ (77,300)
Exercise of warrants for cash [Note 9], shares		(11,966)			(16,683)
Issuance of warrants for services [Note 9]
Balance	$ 24,999	$ 24,999	$ 72,299	$ 24,999	$ 24,999	$ 24,999
Balance, shares	3,955	3,955	15,921	3,955	3,955	3,955
Additional Paid-in Capital [Member]
Balance	$ 93,055,658	$ 91,955,844	$ 91,550,209	$ 92,844,478	$ 91,550,209	$ 91,550,209
Issuance of common stock	119,227			119,227
Stock based compensation - ESOP [Note 9]	163,335	153,338		374,515	302,528
Translation adjustment
Net loss before dividends for the period
Preferred stock dividends
Preferred stock purchased back via cash		(60,619)			(346,046)
Conversion of convertible notes into common shares [Note 9]		175,274			632,233
Issuance of shares for services [Note 9]		30,283			37,782
Exercise of warrants for cash [Note 9]		47,288			47,288
Issuance of warrants for services [Note 9]		77,332			154,746
Balance	93,338,220	92,378,740	91,955,844	93,338,220	92,378,740	92,844,478
AOCI Attributable to Parent [Member]
Balance	(328,627)	(535,652)	(768,656)	(152,797)	(768,656)	(768,656)
Issuance of common stock
Stock based compensation - ESOP [Note 9]
Translation adjustment	281,240	465,517		105,410	698,521
Net loss before dividends for the period
Preferred stock dividends
Preferred stock purchased back via cash
Conversion of convertible notes into common shares [Note 9]
Issuance of shares for services [Note 9]
Exercise of warrants for cash [Note 9]
Issuance of warrants for services [Note 9]
Balance	(47,387)	(70,135)	(535,652)	(47,387)	(70,135)	(152,797)
Retained Earnings [Member]
Balance	(116,172,404)	(98,061,531)	(93,037,142)	(112,570,825)	(93,037,142)	(93,037,142)
Issuance of common stock
Stock based compensation - ESOP [Note 9]
Translation adjustment
Net loss before dividends for the period	(3,690,840)	(4,692,548)		(7,103,722)	(9,468,800)
Preferred stock dividends	(190,442)	(211,819)		(379,139)	(459,956)
Preferred stock purchased back via cash
Conversion of convertible notes into common shares [Note 9]
Issuance of shares for services [Note 9]
Exercise of warrants for cash [Note 9]
Issuance of warrants for services [Note 9]
Balance	$ (120,053,686)	$ (102,965,898)	$ (98,061,531)	$ (120,053,686)	$ (102,965,898)	$ (112,570,825)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,103,722)	$ (9,468,800)
Stock based compensation	374,515	302,528
Issuance of shares for services		37,787
Issuance of warrants for services		154,746
Accretion and amortization expenses	1,153,639	100,909
Change in fair value of derivative liabilities	(82,669)	370,266
(Gain) loss upon convertible promissory notes conversion	(13,132)	90,928
Other expense regarding loss on debt modification	59,161
Non-cash lease expense	178,320
Property and equipment depreciation	2,977	2,977
Changes in operating assets and liabilities:
Accounts receivable, net	(411,440)	(53,732)
Inventory	208,810	(1,010,630)
Deposits and other receivables	348,388	(27,866)
Accounts payable and accrued liabilities	1,062,999	1,010,684
Net cash used in operating activities	(4,222,154)	(8,490,203)
CASH FLOWS FROM FINANCING ACTIVITIES
Redemption of preferred shares		(398,756)
Issuance of common shares, net of issuance costs	119,285
Issuance of preferred shares, net of issuance costs	1,900,000
Exercise of warrants for cash		12,500
Proceeds from (repayments of) convertible notes, net	1,977,579
Proceeds from (repayments of) short term loan and promissory notes, net	773,737
Preferred Stock Dividend	(11,967)	(719,742)
Net cash provided by (used in ) financing activities	4,758,634	(1,105,998)
Net increase (decrease) in cash during the period	536,480	(9,596,201)
Effect of foreign currency translation	92,785	27,076
Cash, beginning of period	570,460	12,066,929
Cash, end of period	1,199,725	2,497,804
Supplemental disclosure of cash flow information:
Interest paid	1,046,621	620,714
Taxes

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS Biotricity Inc. (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014, under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016. Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

BASIS OF PRESENTATION, MEASUREM

BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION	6 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION	2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2023 and 2022 and their accompanying notes. The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2024. The Company’s fiscal year-end is March 31. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated. Reclassifications Certain amounts presented in the prior year period have been reclassified to conform to current period condensed consolidated financial statement presentation. Interest expense related to debt principal, previously recorded as a selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss in the prior year, was reclassified as a non-operating expense. Reverse Stock Split On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six ( 1-for-6 20,846 All issued and outstanding common stock, common stock per share amounts and corresponding balance sheet accounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise and conversion price and the number of shares issuable upon the exercise or conversion of all outstanding stock options, warrants, convertible debt and equity instruments to purchase shares of common stock. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Going Concern, Liquidity and Basis of Presentation The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of September 30, 2023, had an accumulated deficit of $ 120.1 12.6 Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. On August 30, 2021, the Company completed an underwritten public offering of its common stock that concurrently facilitated its listing on the Nasdaq Capital Market. Prior to listing on the Nasdaq Capital Market, the Company had also filed a shelf Registration Statement on Form S-3 (No. 333-255544) with the Securities and Exchange Commission on April 27, 2021, which was declared effective on May 4, 2021. This facilitates better transactional preparedness when the Company seeks to issue equity or debt to potential investors, since it continues to allow the Company to offer its shares to investors only by means of a prospectus, including a prospectus supplement, which forms part of an effective registration statement. As such, the Company has developed and continues to pursue sources of funding that management believes will be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. During the fiscal year ended March 31, 2021, the Company closed a number of private placement offerings of convertible notes, which raised net cash proceeds of $ 11,375,690 499,900 14,545,805 11,756,563 1,476,121 2,355,318 1.9 2.0 0.8 As we proceed with the commercialization of the Bioflux, Biotres, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China and spread globally, causing significant disruption to the global and US economy. On March 20, 2020, the Company announced the precautionary measures taken as well as announcing the business impact related to the coronavirus (COVID-19) pandemic. Though its operations have since returned to a normal state, the extent to which the COVID-19 pandemic may continue to affect the economy and the Company’s operations may depend on future developments. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “ Revenue from Contracts with Customers Both the Bioflux mobile cardiac telemetry device, and the Biotres device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. The Company recognized the following forms of revenue for the three and six months ended September 30, 2023 and 2022: SCHEDULE OF REVENUE RECOGNITION 2023 2022 2023 2022 Three Months Ended Six Months Ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Technology fee sales 2,731,461 2,096,873 5,500,379 3,986,855 Device sales 159,836 284,516 411,683 450,586 Total 2,891,297 2,381,389 5,912,062 4,437,441 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Inventories Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES As of As of $ $ Raw material 1,174,826 1,186,735 Finished goods 953,370 1,150,271 Inventories 2,128,196 2,337,006 Significant accounting estimates and assumptions The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities. ● Fair value of stock options The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. ● Fair value of warrants In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) ● Fair value of derivative liabilities In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. ● Functional currency Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. ● Useful life of property and equipment The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. ● Provisions Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, considering the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. ● Contingencies Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. ● Inventory obsolescence Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. ● Incremental borrowing rate for lease The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was applied during the periods presented when conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Cash Cash includes cash on hand and balances with banks. Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of September 30, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 2,883,978 $ — $ — $ 2,883,978 Derivative liabilities, long-term 1,351,448 — — 1,351,448 Total liabilities at fair value $ 4,235,426 $ — $ — $ 4,235,426 As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 1,008,216 $ — $ — $ 1,008,216 Derivative liabilities, long-term 759,065 — — 759,065 Total liabilities at fair value $ 1,767,281 $ — $ — $ 1,767,281 There were no transfers between fair value hierarchy levels during the three and six months ended September 30, 2023 and 2022. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 years Leasehold improvement 5 years Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease liabilities, current, and lease liabilities, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved . Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relation and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses. Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. The Company also accounts for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815. Accordingly, the Company records, as a discount to convertible notes, the amount bifurcated from the convertibles notes attributed to any derivatives. Debt discounts under these arrangements are amortized over the term of the related debt. Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to consolidated statement of operation in accordance with ASC 480 and ASC 815. Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company adopted this guidance on April 1, 2023 and it did not have a significant impact on the Company’s consolidated financial statements.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	6 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As of September 30, As of March 31, $ $ Trade and other payables 4,530,331 3,435,123 Accrued liabilities 2,119,545 1,607,353 Deferred revenue 8,750 — Total 6,658,626 5,042,476 Trade and other payables and accrued liabilities as at September 30, 2023 and March 31, 2023 included $ 565,399 446,771

CONVERTIBLE PROMISSORY NOTES AN

CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS	6 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS	5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Series A Convertible Promissory Notes : During the year ended March 31, 2021, the Company issued $ 11,275,500 12 For the first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company’s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Outstanding Balance”) could be converted into that number of shares of Common Stock equal to: (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price). For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $ 24.00 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share. Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features. For the Series A Notes, The Company recognized debt issuance costs in the amount of $ 2,301,854 8,088,003 On December 30, 2022, the Company exchanged $ 500,000 121,500 621,500 12 75 December 30, 2023 During the three and six months ended September 30, 2023, the Company recognized discount amortization of $ 16,455 32,291 17,102 As of September 30, 2023, the Company recorded $ 124,337 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Series B Convertible Notes During the year ended March 31, 2021, the Company also issued $ 1,312,500 Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3 -year term from date of issuance and an exercise price that is $ 6.36 per share for 100,000 warrant shares and $ 9.0 per share for 35,417 warrant shares. Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $ 1,240,000 The Company recognized debt issuance costs in the amount of $ 10,000 1,312,500 As of September 30, 2023, the Company recorded accrued interest in the amount of $ 87,566 During the three and six months ended September 30, 2023, the Company redeemed $ 52,049 102,376 62,459 122,851 6,684 13,132 17,094 33,607 In total, as at September 30, 2023, the Company had $ 200,000 55,344 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Series C Convertible Notes During the three months ended June 30, 2023, the Company issued $ 1,017,700 590,000 During the three months ended September 30, 2023, the Company issued additional Series C Notes in the amount of $ 205,000 15 In total, $ 1,812,700 The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15 For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Conversion Amount”) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the “Optional Conversion Price”, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. For Series C Notes, “Mandatory Conversion” of the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty (20) consecutive Trading Days (the “Measurement Period”) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time final closing. The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing. As of September 30, 2023, the Company has not issued the investor warrants and placement agent warrants related to the Series C Notes. These warrants will be issued upon the final closing date of the Series C Notes. Net proceeds to the Company from Series C Notes issuance during the six months ended September 30, 2023 amounted to $ 184,500 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Prior to the final closing date, the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. For the Series C Notes, the Company recognized debt issuance costs of $ 35,362 207,361 168,535 1,005,829 26,833 134,013 During the three and six months ended September 30, 2023, the Company recognized discount amortization of $ 95,183 180,866 1,610,913 As of September 30, 2023, the Company recorded accrued interest in the amount of $ 115,258 Convertible Preferred Note The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $ 1.0 12 At the option of the holder of the Preferred Note, the instrument can be converted upon a subsequent qualified equity or debt round of financing of the Company that raises in excess of $ 15,000,000 The Company may prepay the Preferred Note in whole or in part, after providing fifteen (15) days written notice to the holder, either in cash or by the mutually consented conversion of the Preferred Note and any accrued interest thereon at a 15 There are standard events of default that include non-payment of principal and interest when due and non-performance or observance of any covenant or agreement as applicable. If an event of default is not cured, the Company is obligated to pay the holder the outstanding principal amount plus all accrued and unpaid interest through the date the Preferred Note is paid in full. The Company determined that the optional conversion upon a Qualified Financing qualified was an embedded derivative, and as such, was separated from its debt host. The bifurcation of the embedded derivative resulted in a discount to the Preferred Note in the amount of $ 717,071 3,167 1,995 Other Convertible Notes On January 23, 2023, the Company issued $ 2,000,000 10 45,045 221,621 The conversion of the Other Convertible Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the note holder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes. During the three and six months ended September 30, 2023, the Company recognized discount amortization of $ 55,861 111,115 75,289 Other Short-Term Loans, Promissory Notes and Financing Facilities In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 400,000 9,999 40 13,995 560,000 2,893 6,142 In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $ 800,000 32,000 40 29,556 13,999 1,120,000 29,075 800 10,400 20,800 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $ 600,000 25 December 15, 2023 3 600,000 12,517 On December 30, 2022, the Company extinguished 51,101 270,000 December 31, 2023 248,479 21,521 270,000 Nil Nil 7,304 On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $ 300,000 12,000 40 5,250 11,083 420,000 700,000 28,000 40 24,500 980,000 59,161 567,700 21,000 11,500 3,600 In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the “Revolving Facility”) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $ 1.2 0.3 1,025,399 300,000 1,325,399 On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 400,000 24,000 14 38,705 540,000 105,166 5,143 18,857 On August 11, 2023, the Company issued two short term promissory notes (“August 2023 Notes”), each for a principal amount of $ 250,000 500,000 75,000 $250,000 25,000 250,000 50,000 500,000 25,000 During the six months ended September 30, 2023, the Company received and repaid various short-term promissory notes from individual lenders. As at September 30, 2023, the Company had outstanding principal of $ 75,000 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Total interest expense on the above convertible notes, short-term loan and promissory notes was $ 245,326 25,230 404,596 56,644 Total accretion expense on the above convertible notes, short-term loan and promissory notes was $ 544,697 Nil 1,050,974 Nil

TERM LOAN AND CREDIT AGREEMENT

TERM LOAN AND CREDIT AGREEMENT	6 Months Ended
	Sep. 30, 2023
Term Loan And Credit Agreement
TERM LOAN AND CREDIT AGREEMENT	6. TERM LOAN AND CREDIT AGREEMENT Term Loan On December 21, 2021, the Company entered into a Credit Agreement (“Credit Agreement”) with SWK Funding LLC (“Lender’); as part of this, the Company has borrowed $ 12.4 December 21, 2026 10.5 February 15, 2022 Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. 120,000 600,000 As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $ 50,000 Total costs directly in connection to the debt financing in the amount of $ 193,437 48,484 144,953 12,000,000 The Company also repaid $ 1,574,068 Total costs directly in connection to the loan and fair value of warrants was in the amount of $ 1,042,149 51,724 50,839 102,666 100,909 Total interest expense on the term loan for the three months ended September 30, 2023 and 2022 was $ 499,712 352,667 992,812 701,500 364,000 The Company had accrued interest payable of $ 412,426 239,614 The Company and Lender also entered into a Guarantee and Collateral Agreement (“Collateral Agreement”) wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the “IP Security Agreement”) wherein the Credit Agreement is also secured by the Company’s right title and interest in the Company’s Intellectual Property. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) In connection with the Credit Agreement, the Company issued 9,590 198,713 At September 30, 2023, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender.

FEDERALLY GUARANTEED LOAN

FEDERALLY GUARANTEED LOAN	6 Months Ended
	Sep. 30, 2023
Federally Guaranteed Loan
FEDERALLY GUARANTEED LOAN	7. FEDERALLY GUARANTEED LOAN Economic Injury Disaster Loan (“EIDL”) In April 2020, the Company received $ 370,900 The loan has a term of 30 years 3.75 In May 2021, the Company received an additional $ 499,900 As of September 30, 2023, the Company recorded accrued interest of $ 45,105 65,247 Interest expense on the above loan was $ 8,231 8,230 16,372 16,371

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	6 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES The Company analyzed the compound features of variable conversion and redemption embedded in the series A and series B preferred shares instruments, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the six months ended September 30, 2023 and 2022: SCHEDULE OF DERIVATIVE LIABILITIES 2023 2022 $ $ Derivative liabilities, beginning of period 759,065 352,402 Derivative liabilities recognized pursuant to issuance of Series B preferred shares (Note 9) 642,416 — Change in fair value of derivatives during period (50,033 ) 364,283 Reduction due to preferred shares redeemed — (15,049 ) Conversion to common shares Convertible note modification Convertible note redemption Derivative liabilities, end of period 1,351,448 701,636 The lattice methodology was used to value the derivative components, using the following assumptions during the six months ended September 30, 2023 and 2022: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS 2023 2022 Dividend yield (%) 12 12 Risk-free rate for term (%) 4.90 5.20 3.25 3.80 Volatility (%) 71.9 111.4 85.4 98.4 Remaining terms (Years) 0.34 2.01 1.32 2.75 Stock price ($ per share) 2.14 3.82 4.80 6.00 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the six months ended September 30, 2023 and 2022: SCHEDULE OF DERIVATIVE LIABILITIES 2023 2022 $ $ Balance beginning of period – March 31 1,008,216 520,747 New Issuance 1,942,004 — Conversion to common shares — (139,392 ) Change in fair value of derivative liabilities (32,635 ) 5,983 Convertible note redemption (33,607 ) — Balance end of period – September 30 2,883,978 387,338 The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2023 and 2022, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS 2023 2022 Risk-free rate for term (%) 4.2 5.0 2.34 3.75 Volatility (%) 93.8 105 92.3 99.8 Remaining terms (Years) 1.25 1.50 0.50 0.75 Stock price ($ per share) 2.75 4.20 4.80 10.50

STOCKHOLDERS_ DEFICIENCY AND ME

STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY	6 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY	9. STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY (a) Authorized and Issued Stock As at September 30, 2023, the Company is authorized to issue 125,000,000 125,000,000 0.001 10,000,000 10,000,000 0.001 20,000 20,000 0.001 600 nil 0.001 At September 30, 2023, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled 8,810,248 8,752,505 8,565,795 8,508,052 244,453 244,453 6,304 6,304 220 nil there is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement and outstanding as at September 30, 2023 and March 31, 2023 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) (b ) Series A Preferred Stock The number of Series A Preferred Stock issued and outstanding as of September 30, 2023 and March 31, 2023 was 6,304 The Series A Preferred Stock is junior to the Company’s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the “Purchase Price”) for the Series A Preferred Stock to date has been $ 1,000 Preferred Stock Dividends Dividends shall be paid at the rate of 12 Conversion The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock. Upon which, on a monthly basis, up to 5 0.001 15 Other Adjustments and Rights ● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization. ● The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company’s common stock on an as converted basis. Company Redemption The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110 (c) Series B Preferred Stock and Mezzanine Equity On September 19, 2023, the Company entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale of 220 0.001 9,091 1,900,000 Shares of Series B Preferred Stock and shares of Common Stock of the Company that are issuable upon conversion of, or as dividends on, the Series B Preferred Stock were offered and were issued pursuant to the Prospectus Supplement, filed September 19, 2023, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No. 333-255544) filed with the Securities and Exchange Commission on April 27, 2021, and declared effective May 4, 2021. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) Pursuant to the Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the “Certificate of Designations”) with the Nevada Secretary of State designating 600 10,000 The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock. Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (“Dividends”), in shares of common stock or cash on the stated value at an annual rate of 8 Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $ 3.50 4.99 19.9 Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock. At any time after the earlier of a holder’s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holder’s receipt of a Triggering Event notice, such holder may require the Company to redeem such holder’s shares of Series B Preferred Stock. Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock. The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to 110% Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity A roll-forward of activity is presented below SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY 2023 $ Balance beginning of period – March 31 — Net proceeds received pursuant to the issuance of preferred shares 1,900,000 Recognition of derivative liabilities (Note 8) (642,416 ) Balance end of period – September 30 1,257,584 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) (d) Common share issuances Issuances during the six months ended September 30, 2023 The Company sold 36,897 123,347 119,285 20,846 Issuances during the six months ended September 30, 2022 During the three months ended June 30, 2022, the Company issued 67,395 406,118 302,000 104,118 457,025 50,908 In addition, during the three months ended June 30, 2022, the Company removed 6,683 1,966 42,500 12,500 Lastly, during the three months ended June 30, 2022, the Company issued 695 7,500 During the three months ended September 30, 2022, the Company issued 19,608 135,274 100,000 35,274 175,294 40,020 During the three months ended September 30, 2022, the Company issued 3,796 30,287 (e) Common shares to be issued Activity during the six months ended September 30, 2023 None. Activity during the six months ended September 30, 2022 During the three months ended September 30, 2022, the Company issued 11,966 47,300 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) (f) Warrant issuances, exercises and other activity Warrant exercises and issuances during the six months ended September 30, 2023 None. Warrant exercises and issuances during the six months ended September 30, 2022 During the three months ended June 30, 2022, the Company issued 8,972 77,414 During the three months ended September 30, 2022, the Company issued 19,714 77,332 Warrant activity during the six months ended September 30, 2023 is indicated below: SCHEDULE OF WARRANTS OUTSTANDING Broker Warrants Consultant and Noteholder Warrants Warrants Issued on Convertible Notes Total As at March 31, 2023 139,865 279,341 888,277 1,307,483 Expired/cancelled — (20,884 ) — (20,884 ) Exercised — — — — Issued — — — — As at September 30, 2023 139,865 258,457 888,277 1,286,599 Exercise Price $ 6.36 37.56 $ 2.69 14.40 $ 6.36 9.00 Expiration Date August 2026 to January 2031 December 2023 to December 2032 January 2024 to February 2024 (g) Stock-based compensation 2016 Equity Incentive Plan On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) During the three months ended September 30, 2023 and 2022, the Company granted 3,585 627 3,585 2,325 163,335 153,338 374,515 302,528 1,005,091 960,521 The following table summarizes the stock option activities during the six months ended September 30, 2023: SCHEDULE OF STOCK OPTION ACTIVITIES Number of Options Weighted Average Exercise Price Outstanding at March 31, 2023 1,264,890 $ 9.29 Granted 3,585 $ 2.79 Exercised — $ — Expired/Forfeited (17,397 ) $ 8.52 Outstanding at September 30, 2023 1,251,078 $ 9.30 The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective six month periods ended September 30: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS 2023 2022 Exercise price ($) 2.79 4.80 Risk free interest rate (%) 3.85 4.06 Expected term (Years) 10.0 5.00 Expected volatility (%) 117.1 113.9 Expected dividend yield (%) 0.00 0.00 Fair value of option ($) 2.30 3.92 Expected forfeiture (attrition) rate (%) 0.00 0.00 2023 Equity Incentive Plan and the Employee Stock Purchase Plans On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Plan’s administrator. The 2023 Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). An aggregate of 5,000,000 The Company also adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible employees of the Company and the Company’s designated subsidiaries the ability to purchase shares of the Company’s Common Stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase Common Stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator (the “Administrator”). In no event can any single offering period be longer than 27 months. The purchase price (the “Purchase Price”) for each offering will be established by the Administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (“Section 423 Offering”), in no case may such Purchase Price be less than the lesser of (i) an amount equal to 85 percent of the fair market value on the commencement date, or (ii) an amount not less than 85 percent of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 Business Days before the end of the offering period (the “Offering Period”). Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participant’s accumulated payroll deductions will buy at the Purchase Price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 Business Days before the end of an Offering Period (or such earlier date as determined by the Administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant’s lifetime, purchase rights under the ESPP shall be exercisable only by the participant. There were no issuances under either the 2023 Plan or the ESPP as of September 30, 2023. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)

OPERATING LEASE RIGHT-OF-USE AS

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS	6 Months Ended
	Sep. 30, 2023
Operating Lease Right-of-use Assets And Lease Obligations
OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS	10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS The Company has one operating lease primarily for office and administration. During December 2021, the Company entered into a new lease agreement. The Company paid an $ 85,000 When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied was 11.4 3.1 2.5 SCHEDULE OF OPERATING LEASES OBLIGATIONS 2023 2022 Right of Use Asset $ $ Beginning balance at March 31 1,587,492 1,242,700 New leases — — Amortization (178,320 ) (102,491 ) Ending balance at September 30 1,409,172 1,140,209 2023 2022 Lease Liability $ $ Beginning balance at March 31 1,722,095 1,330,338 New leases — — Repayment and interest accretion, net (190,864 ) (100,450 ) Ending balance at September 30 1,531,231 1,229,888 September 30, March 31, Lease Liability $ $ Current portion of operating lease liability 364,028 335,608 Noncurrent portion of operating lease liability 1,167,203 1,386,487 The operating lease expense was $ 140,759 89,717 279,493 211,452 282,209 172,557 The following table represents the contractual undiscounted cash flows for lease obligations as of September 30, 2023: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar year $ 2023 112,005 2024 552,293 2025 600,288 2026 565,359 Total undiscounted lease liability Less imputed interest (298,714 ) Total 1,531,231 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES There are no claims against the Company that were assessed as significant, which were outstanding as at September 30, 2023 or March 31, 2023 and, consequently, no provision for such has been recognized in the condensed consolidated financial statements.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	12. PROPERTY AND EQUIPMENT During the three and six months ended September 30, 2023 and 2022, the Company did not purchase any property and equipment. The Company recognized depreciation expense for these assets in the amount of $ 1,489 2,977 SCHEDULE OF PROPERTY AND EQUIPMENT Cost Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2023 16,839 12,928 29,767 Additions — — — Disposals — — — Balance at September 30, 2023 16,839 12,928 29,767 Accumulated depreciation Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2023 4,675 3,586 8,261 Depreciation for the period 1,686 1,291 2,977 Disposals — — — Balance at September 30, 2023 6,361 4,877 11,238 Net book value Balance at March 31, 2023 12,164 9,432 21,506 Balance at September 30, 2023 10,478 8,051 18,529

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events during the period from October 1 to November 14, 2023, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following material subsequent events: ● To expand the Company’s IP portfolio of trade secrets and patents, and protect its product developments as valuable to the Company and its shareholders, on October 4, the Company announced the filing of a patent application for its Biotres device, a state-of-the art advancement in remote patient monitoring and cardiac care for clinicians. On October 10, the Company announced a patent filing for its Bioheart device, a state-of-the art advancement in remote patient monitoring and cardiac care for consumers. Further, on October 31, the Company announced a further expansion of its Biotres platform, with the Biotres Pro, with enhancements that enable cellular back up and connectivity. ● Between October 2 and November 3, a holder of Series B Preferred Shares converted 15 150,000 1,063 1.71 0.80 202,869 ● During October and November 2023, the Company issued $ 1.25 1 12

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “ Revenue from Contracts with Customers Both the Bioflux mobile cardiac telemetry device, and the Biotres device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. The Company recognized the following forms of revenue for the three and six months ended September 30, 2023 and 2022: SCHEDULE OF REVENUE RECOGNITION 2023 2022 2023 2022 Three Months Ended Six Months Ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Technology fee sales 2,731,461 2,096,873 5,500,379 3,986,855 Device sales 159,836 284,516 411,683 450,586 Total 2,891,297 2,381,389 5,912,062 4,437,441 BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Inventories	Inventories Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES As of As of $ $ Raw material 1,174,826 1,186,735 Finished goods 953,370 1,150,271 Inventories 2,128,196 2,337,006
Significant accounting estimates and assumptions	Significant accounting estimates and assumptions The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities. ● Fair value of stock options The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. ● Fair value of warrants In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars) ● Fair value of derivative liabilities In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. ● Functional currency Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. ● Useful life of property and equipment The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. ● Provisions Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, considering the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. ● Contingencies Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. ● Inventory obsolescence Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. ● Incremental borrowing rate for lease The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was applied during the periods presented when conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.
Cash	Cash Cash includes cash on hand and balances with banks.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.
Accounts Receivable	Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of September 30, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 2,883,978 $ — $ — $ 2,883,978 Derivative liabilities, long-term 1,351,448 — — 1,351,448 Total liabilities at fair value $ 4,235,426 $ — $ — $ 4,235,426 As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 1,008,216 $ — $ — $ 1,008,216 Derivative liabilities, long-term 759,065 — — 759,065 Total liabilities at fair value $ 1,767,281 $ — $ — $ 1,767,281 There were no transfers between fair value hierarchy levels during the three and six months ended September 30, 2023 and 2022. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 years Leasehold improvement 5 years
Impairment for Long-Lived Assets	Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment
Leases	Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease liabilities, current, and lease liabilities, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Research and Development	Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved .
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relation and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.
Stock Based Compensation	Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.
Convertible Notes Payable and Derivative Instruments	Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. The Company also accounts for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815. Accordingly, the Company records, as a discount to convertible notes, the amount bifurcated from the convertibles notes attributed to any derivatives. Debt discounts under these arrangements are amortized over the term of the related debt.
Series B Convertible Preferred Stock	Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to consolidated statement of operation in accordance with ASC 480 and ASC 815.
Preferred Shares Extinguishments	Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. BIOTRICITY INC. SEPTEMBER 30, 2023 (Unaudited) (Expressed in US dollars)
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company adopted this guidance on April 1, 2023 and it did not have a significant impact on the Company’s consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF REVENUE RECOGNITION	The Company recognized the following forms of revenue for the three and six months ended September 30, 2023 and 2022: SCHEDULE OF REVENUE RECOGNITION 2023 2022 2023 2022 Three Months Ended Six Months Ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Technology fee sales 2,731,461 2,096,873 5,500,379 3,986,855 Device sales 159,836 284,516 411,683 450,586 Total 2,891,297 2,381,389 5,912,062 4,437,441
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES As of As of $ $ Raw material 1,174,826 1,186,735 Finished goods 953,370 1,150,271 Inventories 2,128,196 2,337,006
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS	The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of September 30, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 2,883,978 $ — $ — $ 2,883,978 Derivative liabilities, long-term 1,351,448 — — 1,351,448 Total liabilities at fair value $ 4,235,426 $ — $ — $ 4,235,426 As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Derivative liabilities, short-term $ 1,008,216 $ — $ — $ 1,008,216 Derivative liabilities, long-term 759,065 — — 759,065 Total liabilities at fair value $ 1,767,281 $ — $ — $ 1,767,281
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES	SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 years Leasehold improvement 5 years

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	6 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As of September 30, As of March 31, $ $ Trade and other payables 4,530,331 3,435,123 Accrued liabilities 2,119,545 1,607,353 Deferred revenue 8,750 — Total 6,658,626 5,042,476

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	6 Months Ended
	Sep. 30, 2023
Debt Instrument [Line Items]
SCHEDULE OF DERIVATIVE LIABILITIES	SCHEDULE OF DERIVATIVE LIABILITIES 2023 2022 $ $ Derivative liabilities, beginning of period 759,065 352,402 Derivative liabilities recognized pursuant to issuance of Series B preferred shares (Note 9) 642,416 — Change in fair value of derivatives during period (50,033 ) 364,283 Reduction due to preferred shares redeemed — (15,049 ) Conversion to common shares Convertible note modification Convertible note redemption Derivative liabilities, end of period 1,351,448 701,636
SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS	The lattice methodology was used to value the derivative components, using the following assumptions during the six months ended September 30, 2023 and 2022: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS 2023 2022 Dividend yield (%) 12 12 Risk-free rate for term (%) 4.90 5.20 3.25 3.80 Volatility (%) 71.9 111.4 85.4 98.4 Remaining terms (Years) 0.34 2.01 1.32 2.75 Stock price ($ per share) 2.14 3.82 4.80 6.00
Convertible Debt [Member]
Debt Instrument [Line Items]
SCHEDULE OF DERIVATIVE LIABILITIES	SCHEDULE OF DERIVATIVE LIABILITIES 2023 2022 $ $ Balance beginning of period – March 31 1,008,216 520,747 New Issuance 1,942,004 — Conversion to common shares — (139,392 ) Change in fair value of derivative liabilities (32,635 ) 5,983 Convertible note redemption (33,607 ) — Balance end of period – September 30 2,883,978 387,338
SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS	The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2023 and 2022, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS 2023 2022 Risk-free rate for term (%) 4.2 5.0 2.34 3.75 Volatility (%) 93.8 105 92.3 99.8 Remaining terms (Years) 1.25 1.50 0.50 0.75 Stock price ($ per share) 2.75 4.20 4.80 10.50

STOCKHOLDERS_ DEFICIENCY AND _2

STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY (Tables)	6 Months Ended
	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY	SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY 2023 $ Balance beginning of period – March 31 — Net proceeds received pursuant to the issuance of preferred shares 1,900,000 Recognition of derivative liabilities (Note 8) (642,416 ) Balance end of period – September 30 1,257,584
SCHEDULE OF WARRANTS OUTSTANDING	Warrant activity during the six months ended September 30, 2023 is indicated below: SCHEDULE OF WARRANTS OUTSTANDING Broker Warrants Consultant and Noteholder Warrants Warrants Issued on Convertible Notes Total As at March 31, 2023 139,865 279,341 888,277 1,307,483 Expired/cancelled — (20,884 ) — (20,884 ) Exercised — — — — Issued — — — — As at September 30, 2023 139,865 258,457 888,277 1,286,599 Exercise Price $ 6.36 37.56 $ 2.69 14.40 $ 6.36 9.00 Expiration Date August 2026 to January 2031 December 2023 to December 2032 January 2024 to February 2024
SCHEDULE OF STOCK OPTION ACTIVITIES	The following table summarizes the stock option activities during the six months ended September 30, 2023: SCHEDULE OF STOCK OPTION ACTIVITIES Number of Options Weighted Average Exercise Price Outstanding at March 31, 2023 1,264,890 $ 9.29 Granted 3,585 $ 2.79 Exercised — $ — Expired/Forfeited (17,397 ) $ 8.52 Outstanding at September 30, 2023 1,251,078 $ 9.30
SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS	The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective six month periods ended September 30: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS 2023 2022 Exercise price ($) 2.79 4.80 Risk free interest rate (%) 3.85 4.06 Expected term (Years) 10.0 5.00 Expected volatility (%) 117.1 113.9 Expected dividend yield (%) 0.00 0.00 Fair value of option ($) 2.30 3.92 Expected forfeiture (attrition) rate (%) 0.00 0.00

OPERATING LEASE RIGHT-OF-USE _2

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables)	6 Months Ended
	Sep. 30, 2023
Operating Lease Right-of-use Assets And Lease Obligations
SCHEDULE OF OPERATING LEASES OBLIGATIONS	SCHEDULE OF OPERATING LEASES OBLIGATIONS 2023 2022 Right of Use Asset $ $ Beginning balance at March 31 1,587,492 1,242,700 New leases — — Amortization (178,320 ) (102,491 ) Ending balance at September 30 1,409,172 1,140,209 2023 2022 Lease Liability $ $ Beginning balance at March 31 1,722,095 1,330,338 New leases — — Repayment and interest accretion, net (190,864 ) (100,450 ) Ending balance at September 30 1,531,231 1,229,888 September 30, March 31, Lease Liability $ $ Current portion of operating lease liability 364,028 335,608 Noncurrent portion of operating lease liability 1,167,203 1,386,487
SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION	The following table represents the contractual undiscounted cash flows for lease obligations as of September 30, 2023: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar year $ 2023 112,005 2024 552,293 2025 600,288 2026 565,359 Total undiscounted lease liability Less imputed interest (298,714 ) Total 1,531,231

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT Cost Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2023 16,839 12,928 29,767 Additions — — — Disposals — — — Balance at September 30, 2023 16,839 12,928 29,767 Accumulated depreciation Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2023 4,675 3,586 8,261 Depreciation for the period 1,686 1,291 2,977 Disposals — — — Balance at September 30, 2023 6,361 4,877 11,238 Net book value Balance at March 31, 2023 12,164 9,432 21,506 Balance at September 30, 2023 10,478 8,051 18,529

SCHEDULE OF REVENUE RECOGNITION

SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product Information [Line Items]
Total	$ 2,891,297	$ 2,381,389	$ 5,912,062	$ 4,437,441
Technology Fees [Member]
Product Information [Line Items]
Total	2,731,461	2,096,873	5,500,379	3,986,855
Device Sales [Member]
Product Information [Line Items]
Total	$ 159,836	$ 284,516	$ 411,683	$ 450,586

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Sep. 30, 2023	Mar. 31, 2023
Accounting Policies [Abstract]
Raw material	$ 1,174,826	$ 1,186,735
Finished goods	953,370	1,150,271
Inventories	$ 2,128,196	$ 2,337,006

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Sep. 30, 2023	Mar. 31, 2023
Platform Operator, Crypto-Asset [Line Items]
Derivative liabilities, short-term	$ 2,883,978	$ 1,008,216
Derivative liabilities, long-term	1,351,448	759,065
Total liabilities at fair value	4,235,426	1,767,281
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liabilities, short-term
Derivative liabilities, long-term
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liabilities, short-term
Derivative liabilities, long-term
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liabilities, short-term	2,883,978	1,008,216
Derivative liabilities, long-term	1,351,448	759,065
Total liabilities at fair value	$ 4,235,426	$ 1,767,281

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)	Sep. 30, 2023
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Office equipment	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Office equipment	5 years

BASIS OF PRESENTATION, MEASUR_2

BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) - USD ($)			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 25, 2023	Jun. 29, 2023	Sep. 30, 2023	Sep. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Jun. 19, 2023
Reverse stock, shares split		1-for-6
Accumulated deficit			$ 120,053,686	$ 120,053,686	$ 112,570,825
Working capital deficiency			12,600,000	12,600,000
Proceeds from issuance of debt						$ 11,756,563	$ 11,375,690
Proceeds from issuance initial public offering						14,545,805
Proceeds from short term debt					1,476,121
Debt conversion converted instrument amount	$ 15,000,000				$ 2,355,318
Net proceeds from additional convertible notes				$ 717,071
Series B Preferred Stock [Member]
Debt conversion converted instrument amount			2,000,000
Net proceeds from additional convertible notes			1,900,000
Repayment of short term loans and promissory notes, net			$ 800,000
Economic Injury Disaster Loan [Member]
Proceeds from issuance of debt						$ 499,900
Common Stock [Member]
Issuance of common stock			20,846	20,846				20,846

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Trade and other payables	$ 4,530,331	$ 3,435,123
Accrued liabilities	2,119,545	1,607,353
Deferred revenue	8,750
Total	$ 6,658,626	$ 5,042,476

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($)	Sep. 30, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Trade and other payables and accrued liabilities	$ 565,399	$ 446,771

CONVERTIBLE PROMISSORY NOTES _2

CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) - USD ($)									1 Months Ended			3 Months Ended			6 Months Ended		9 Months Ended	12 Months Ended
	Sep. 25, 2023	Aug. 11, 2023	Jul. 18, 2023	Jul. 13, 2023	Mar. 29, 2023	Jan. 23, 2023	Dec. 30, 2022	Dec. 21, 2021	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Nov. 30, 2022
Short-Term Debt [Line Items]
Issuance of debt																			$ 11,756,563	$ 11,375,690
Deferred finance costs								$ 193,437
Adjustment for amortization												$ 16,455			$ 32,291
Face value								$ 12,400,000													$ 364,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									9,590			9,590			9,590		9,590
Convertible note issuances																	$ 717,071
Gains losses on extinguishment of debt												$ 6,684		$ (40,020)	$ 13,132	$ (90,928)
Derivative liabilities									$ 4,235,426			4,235,426			4,235,426		4,235,426	$ 1,767,281
Accretion Expense												26,833			134,013
Debt converted amount	$ 15,000,000																	2,355,318
Accretion and amortization expense												3,167					3,167
Fair value of embedded derivative liability									1,995			1,995			1,995		1,995
Gross proceeds																		1,476,121
Maturity date								Dec. 21, 2026
Line of Credit Facility, Revolving Credit Conversion to Term Loan, Description										In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $
Financing Receivable, Revolving, Converted to Term Loan										$ 1,200,000			$ 1,200,000
Line of Credit Facility, Capacity Available for Trade Purchases									300,000	$ 300,000		300,000	300,000		300,000		300,000
Increase (Decrease) in Accounts Receivable									1,025,399						411,440	53,732
Line of Credit Facility, Annual Principal Payment									1,325,399
Convertible debt									245,326			245,326		25,230	245,326	25,230	245,326
Interest expense															404,596	56,644
Other Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate stated percentage						10%
Convertible notes payable						$ 2,000,000
Convertible notes payable						45,045
Convertible notes payable						$ 221,621
Notes Payable, Other Payables [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount									75,289			75,289			75,289		75,289
Adjustment for amortization												55,861			111,115
Eighteen Month Anniversary [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate stated percentage	12%
Face value	$ 1,000,000
Series A Preferred Stock [Member]
Short-Term Debt [Line Items]
Convertible notes payable remaining									200,000			200,000			$ 200,000		200,000
Series B Preferred Stock [Member]
Short-Term Debt [Line Items]
Debt conversion description															Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount
Convertible note issuances															$ 1,900,000
Convertible notes payable remaining									55,344			55,344			55,344		55,344
Debt converted amount															2,000,000
Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Accrued interest									115,258			115,258			115,258		115,258
Conversion Notice [Member]
Short-Term Debt [Line Items]
Debt conversion description																				The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.
Series A Convertible Note Holders [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							51,101
Warrant [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																				The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share.
Preferred Stock [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate stated percentage	15%
Two Series A Notes [Member]
Short-Term Debt [Line Items]
Issuance of debt																				$ 11,275,500
Debt instrument interest rate stated percentage																				12%
Two Series A Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Placement agent fees description																				The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing.
Series A Notes One [Member]
Short-Term Debt [Line Items]
Description of conversion terms for debt instrument																				(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price).
Debt conversion description																				the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest.
Series A Notes One [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																				The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.
Series A Notes Two [Member]
Short-Term Debt [Line Items]
Description of conversion terms for debt instrument																				75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date.
Debt conversion description																				the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00  per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00  per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest.
Conversion price																				$ 24
Series A Notes [Member]
Short-Term Debt [Line Items]
Deferred finance costs																			2,301,854
Debt instrument unamortized discount									17,102			17,102			17,102		17,102		8,088,003
Series A Notes [Member] | Additional Collateralized Bridge Loan Agreement [Member]
Short-Term Debt [Line Items]
Deferred finance costs			$ 28,000
Series A Note [Member]
Short-Term Debt [Line Items]
Debt outstanding							$ 500,000
Accrued interest									124,337			124,337			124,337		124,337
New Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate stated percentage							12%
Debt outstanding							$ 621,500
Debt instrument accrued interest							$ 121,500
Debt instrument interest rate during period							75%
Debt instrument maturity date							December 30, 2023
Series B Notes [Member]
Short-Term Debt [Line Items]
Debt conversion description																				The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage.
Deferred finance costs																			10,000
Debt instrument unamortized discount																			$ 1,312,500
Convertible note issuances																				$ 1,240,000
Series B Notes [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Face value																				$ 1,312,500
Series B Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants and Rights Outstanding, Term																				3 years
Series B Notes [Member] | Warrant One [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 6.36
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																				100,000
Series B Notes [Member] | Warrant Two [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 9
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																				35,417
Series B Note [Member]
Short-Term Debt [Line Items]
Accrued interest									87,566			87,566			87,566		87,566
Face value									17,094			17,094			17,094		17,094
Redemption of convertible notes												52,049			102,376
Payment redeemed cash												62,459			122,851
Gains losses on extinguishment of debt												6,684			13,132
Derivative liabilities									$ 33,607			33,607			$ 33,607		$ 33,607
Series C Notes [Member]
Short-Term Debt [Line Items]
Issuance of debt												$ 205,000	$ 1,017,700
Debt instrument interest rate stated percentage									15%			15%			15%		15%
Description of conversion terms for debt instrument															(i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.
Debt conversion description															the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty (20) consecutive Trading Days (the “Measurement Period”) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00  per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.
Debt instrument unamortized discount									$ 1,610,913			$ 1,610,913			$ 1,610,913		$ 1,610,913
Adjustment for amortization												95,183			180,866
Convertible note issuances															184,500
Debt issuance costs												35,362			207,361
Debt instrument derivative liabilities												168,535			1,005,829
Series C Notes [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Face value									1,812,700			1,812,700			$ 1,812,700		1,812,700	$ 590,000
Series C Notes [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description															The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes.
Series C Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Placement agent fees description															The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time final closing.
Series C Notes [Member] | Warrant [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description															The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing.
Short-term Bridge Loan Agreement [Member]
Short-Term Debt [Line Items]
Adjustment for amortization												2,893			$ 6,142
Short-term Bridge Loan Agreement [Member] | Collateralized Merchant Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs				$ 24,000							$ 9,999
Debt instrument unamortized discount									5,143			5,143			5,143		5,143
Debt outstanding				540,000					105,166		560,000	105,166			105,166		105,166
Adjustment for amortization												18,857			18,857
Gross proceeds				$ 400,000							$ 400,000
Debt instrument term				98 days							280 days
Debt instrument periodic payment				$ 38,705							$ 13,995
Short-term Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs											32,000
Gross proceeds											800,000
Short-term Bridge Loan Agreement [Member] | Additional Collateralized Bridge Loan Agreement [Member]
Short-Term Debt [Line Items]
Gross proceeds			700,000
Short-term Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount									800			800			800		800
Debt outstanding									29,075		$ 1,120,000	29,075			29,075		29,075
Adjustment for amortization												10,400			20,800
Debt instrument term					280 days						280 days
Debt instrument periodic payment											$ 29,556
Short-term Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | First Four Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment											13,999
Promissory Note Agreement [Member] | Individual Investor [Member]
Short-Term Debt [Line Items]
Debt outstanding									600,000		$ 600,000	600,000			600,000		600,000
Debt instrument interest rate during period											25%
Accrued interest									12,517			12,517			12,517		12,517
Maturity date											Dec. 15, 2023
Early payment penalty provision percentage											3%
New Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount
Debt outstanding									270,000			270,000			270,000		270,000
Adjustment for amortization															7,304
Face value							$ 270,000
Maturity date							Dec. 31, 2023
Debt instrument, fair value disclosure							$ 248,479
Adjustment carrying value and principal amount							$ 21,521
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs					$ 12,000
Debt outstanding					420,000
Gross proceeds					300,000
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | First Four Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment					5,250
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | Remaining Thirty Six Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment					$ 11,083
Additional Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount									21,000			21,000			21,000		21,000
Debt outstanding			$ 980,000						567,700			567,700			567,700		567,700
Adjustment for amortization												11,500			3,600
Debt instrument term			280 days
Debt instrument periodic payment			$ 24,500
Loss on amendment of debt			$ 59,161
Two Short Term Promissory Notes [Member]
Short-Term Debt [Line Items]
Debt outstanding									500,000			500,000			500,000		500,000
Accrued interest									25,000			25,000			25,000		25,000
Face value		$ 250,000							250,000			250,000			250,000		250,000
Administrative fees		75,000
Administrative fees												25,000
Administrative fees												50,000
Two Short Term Promissory Notes [Member] | One Investor [Member]
Short-Term Debt [Line Items]
Debt outstanding		$ 500,000
Short-Term Debt [Member]
Short-Term Debt [Line Items]
Face value									$ 75,000			75,000			75,000		$ 75,000
Promissory Note [Member]
Short-Term Debt [Line Items]
Accretion expense												$ 544,697		$ 1,050,974

TERM LOAN AND CREDIT AGREEMENT

TERM LOAN AND CREDIT AGREEMENT (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 21, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Nov. 30, 2022
Cash and Cash Equivalents [Line Items]
Face amount	$ 12,400,000						$ 364,000
Maturity date	Dec. 21, 2026
Accrue interest	10.50%
Debt instrument date	Feb. 15, 2022
Debt instrument payment terms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances.
Origination fee	$ 120,000
Exit fees	600,000
Debt financing	193,437
Professional fee	48,484
Fee amount	144,953
Gross proceeds	12,000,000
Repayment of short term debt	1,574,068
Fair value of warrants	1,042,149
Amortization of debt discount expense		$ 51,724	$ 50,839	$ 102,666	$ 100,909
Total interest expense		753,268	403,551	1,413,780	791,940
Interest payable current		$ 412,426		$ 412,426		$ 239,614
Warrants issued		9,590		9,590
Issuance of warrants	198,713
Term Loan [Member]
Cash and Cash Equivalents [Line Items]
Total interest expense		$ 499,712	$ 352,667	$ 992,812	$ 701,500
Cash [Member]
Cash and Cash Equivalents [Line Items]
Debt financing	$ 50,000

FEDERALLY GUARANTEED LOAN (Deta

FEDERALLY GUARANTEED LOAN (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
	Dec. 21, 2021	May 31, 2021	Apr. 30, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023
Short-Term Debt [Line Items]
Company received an additional	$ 12,000,000
Interest expense				$ 753,268	$ 403,551	$ 1,413,780	$ 791,940
Economic Injury Disaster Loan [Member]
Short-Term Debt [Line Items]
Company received an additional		$ 499,900	$ 370,900
Debt instrument description			The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in its first 12 months
Debt instrument term			30 years
Interest rate			3.75%
Accrued interest				45,105		45,105		$ 65,247
Interest expense				$ 8,231	$ 8,230	$ 16,372	$ 16,371

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES (Details) - USD ($)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Balance beginning of period – March 31	$ 759,065	$ 352,402
Derivative liabilities recognized pursuant to issuance of Series B preferred shares (Note 9)	642,416
Change in fair value of derivative liabilities	(50,033)	364,283
Reduction due to preferred shares redeemed		(15,049)
Balance end of period – September 30	1,351,448	701,636
Convertible Debt [Member]
Debt Instrument [Line Items]
Balance beginning of period – March 31	1,008,216	520,747
Change in fair value of derivative liabilities	(32,635)	5,983
Conversion to common shares		(139,392)
Convertible note redemption	(33,607)
Balance end of period – September 30	2,883,978	387,338
New Issuance	$ 1,942,004

SCHEDULE OF DERIVATIVE COMPONEN

SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details)	6 Months Ended
	Sep. 30, 2023 $ / shares	Sep. 30, 2022 $ / shares
Minimum [Member]
Derivative [Line Items]
Stock price	$ 2.14	$ 4.80
Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Stock price	2.75	4.80
Maximum [Member]
Derivative [Line Items]
Stock price	3.82	6
Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Stock price	$ 4.20	$ 10.50
Measurement Input, Expected Dividend Rate [Member]
Derivative [Line Items]
Derivative liability, measurement input	12	12
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	4.90	3.25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	4.2	2.34
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	5.20	3.80
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	5	3.75
Measurement Input, Price Volatility [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	71.9	85.4
Measurement Input, Price Volatility [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	93.8	92.3
Measurement Input, Price Volatility [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	111.4	98.4
Measurement Input, Price Volatility [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	105	99.8
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Remaining terms	4 months 2 days	1 year 3 months 25 days
Measurement Input, Expected Term [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Remaining terms	1 year 3 months	6 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Remaining terms	2 years 3 days	2 years 9 months
Measurement Input, Expected Term [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Remaining terms	1 year 6 months	9 months

SCHEDULE OF SERIES B PREFERRED

SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) - USD ($)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Balance beginning of period – March 31
Net proceeds received pursuant to the issuance of preferred shares	1,900,000
Recognition of derivative liabilities (Note 8)	(642,416)
Balance end of period – September 30	$ 1,257,584

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details)	6 Months Ended
	Sep. 30, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at March 31, 2023	1,307,483
Expired/cancelled	(20,884)
Exercised
Issued
As at September 30, 2023	1,286,599
Broker Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at March 31, 2023	139,865
Expired/cancelled
Exercised
Issued
As at September 30, 2023	139,865
Expiration Date	August 2026 to January 2031
Broker Warrants [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 6.36
Broker Warrants [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 37.56
Consultant Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at March 31, 2023	279,341
Expired/cancelled	(20,884)
Exercised
Issued
As at September 30, 2023	258,457
Expiration Date	December 2023 to December 2032
Consultant Warrants [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 2.69
Consultant Warrants [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 14.40
Warrants Issued on Conversion of Convertible Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at March 31, 2023	888,277
Expired/cancelled
Exercised
Issued
As at September 30, 2023	888,277
Expiration Date	January 2024 to February 2024
Warrants Issued on Conversion of Convertible Notes [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 6.36
Warrants Issued on Conversion of Convertible Notes [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price | $ / shares	$ 9

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITIES (Details) - $ / shares	3 Months Ended			6 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average exercise price, ending outstanding	$ 2.30		$ 3.92	$ 2.30
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, beginning outstanding	1,251,078	1,264,890		1,264,890
Weighted average exercise price, beginning outstanding	$ 9.30	$ 9.29		$ 9.29
Number of options, granted		3,585
Weighted average exercise price, granted		$ 2.79
Number of options, exercised
Number of options, expired/forfeited		(17,397)
Weighted average exercise price, expired/forfeited		$ 8.52
Number of options, ending outstanding		1,251,078
Weighted average exercise price, ending outstanding		$ 9.30

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) - $ / shares	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Exercise price	$ 2.79	$ 4.80
Risk free interest rate	3.85%	4.06%
Expected term	10 years	5 years
Expected volatility	117.10%	113.90%
Expected dividend yield	0%	0%
Fair value of option	$ 2.30	$ 3.92
Expected forfeiture (attrition) rate	0%	0%

STOCKHOLDERS_ DEFICIENCY AND _3

STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY (Details Narrative) - USD ($)		3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 19, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Jun. 19, 2023	Feb. 02, 2016
Class of Stock [Line Items]
Common stock shares authorized		125,000,000			125,000,000		125,000,000
Common stock, par value		$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares authorized		10,000,000			10,000,000		10,000,000
Preferred stock convertible conversion price		$ 0.001			$ 0.001		$ 0.001
Common stock, shares issued		8,565,795			8,565,795		8,508,052
Common stock, other shares, outstanding		244,453			244,453		244,453
Special voting rights					there is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement and outstanding as at September 30, 2023 and March 31, 2023
Debt instrument redemption price percentage					110%
Gross proceeds					$ 1,900,000
Stock issued during period share conversion of convertible securities					36,897
Gross proceeds					$ 123,347
Net amount					119,285
Stock issued during period shares			47,300
Common shares for services received			3,796	695
Common shares for services received, value			$ 30,287	$ 7,500
Stock-based compensation					$ 374,515	$ 302,528
Vested		1,005,091	960,521		1,005,091	960,521
2016 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share based payment award number of shares authorized									3,750,000
Stock options granted		3,585	627		3,585	2,325
Stock-based compensation		$ 163,335	$ 153,338		$ 374,515	$ 302,528
2023 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share based payment award number of shares available for issuance							5,000,000
Selling, General and Administrative Expenses [Member]
Class of Stock [Line Items]
Warrants and rights outstanding			$ 77,332	$ 77,414		77,332
Issuance of Common Shares [Member]
Class of Stock [Line Items]
Number shares removed previously to be issued				6,683
Issuance of Common Shares [Member] | Minimum [Member]
Class of Stock [Line Items]
Cancellation of to be issued shares				$ 42,500
Convertible Promissory Notes [Member]
Class of Stock [Line Items]
Stock issued during period share conversion of convertible securities			19,608	67,395
Debts instrument settlement amount			$ 135,274	$ 406,118
Convertible notes payable			100,000	302,000		100,000
Carrying amount of conversion and redemption			35,274	104,118
Debt instrument fair value			175,294	457,025		$ 175,294
Loss on conversion of convertible promissory notes			$ 40,020	$ 50,908
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues		57,743			57,743
Stock issued		20,846			20,846			20,846
Stock issued during period shares			11,966			11,966
Warrant [Member]
Class of Stock [Line Items]
Stock issued during period shares				1,966
Stock issued during period value warrants exercise				$ 12,500
Purchase Agreement [Member]
Class of Stock [Line Items]
Debt instrument redemption price percentage					110%
Purchase Agreement [Member] | Beneficiary [Member]
Class of Stock [Line Items]
Ownership percentage	4.99%
Shareholders [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues					8,810,248		8,752,505
Executive [Member] | Warrant [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues				8,972		19,714
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		20,000			20,000		20,000
Preferred stock convertible conversion price		$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares outstanding		6,304			6,304		6,304
Preferred stock, shares issued		6,304			6,304		6,304
Preferred stock, liquidation preference		$ 1,000			$ 1,000
Preferred stock dividend rate percentage					12%
Debt instrument redemption price percentage					5%
Preferred stock convertible conversion price		0.001			$ 0.001
Volume weighted average price percentage					15%
Initial conversion price		$ 3.50			$ 3.50
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		600			600
Preferred stock convertible conversion price	$ 0.001	$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares outstanding		220			220
Preferred stock, shares issued	220	220			220
Preferred stock convertible purchase price	$ 9,091
Gross proceeds	$ 1,900,000
Debt conversion description					Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount
Series B Preferred Stock [Member] | Purchase Agreement [Member]
Class of Stock [Line Items]
Preferred stock convertible conversion price	$ 10,000
Preferred stock, shares issued	600
Stated value percentage	8%
Series B Preferred Stock [Member] | Purchase Agreement [Member] | Beneficiary [Member]
Class of Stock [Line Items]
Ownership percentage	19.90%

SCHEDULE OF OPERATING LEASES OB

SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) - USD ($)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023
Operating Lease Right-of-use Assets And Lease Obligations
Operating lease right-of-use asset, beginning balance	$ 1,587,492	$ 1,242,700
Right of use asset, new leases
Right of use asset, amortization	(178,320)	(102,491)
Operating lease right-of-use asset, ending balance	1,409,172	1,140,209
Operating lease liability, beginning balance	1,722,095	1,330,338
Lease liability, new leases
Lease liability, repayment and interest accretion, net	(190,864)	(100,450)
Operating lease liability, ending balance	1,531,231	1,229,888
Current portion of operating lease liability	364,028	335,608	$ 335,608
Noncurrent portion of operating lease liability	$ 1,167,203	$ 1,386,487	$ 1,386,487

SCHEDULE OF CONTRACTUAL UNDISCO

SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) - USD ($)	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022
Operating Lease Right-of-use Assets And Lease Obligations
2023	$ 112,005
2024	552,293
2025	600,288
2026	565,359
Less imputed interest	(298,714)
Total	$ 1,531,231	$ 1,722,095	$ 1,229,888	$ 1,330,338

OPERATING LEASE RIGHT-OF-USE _3

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average rate	11.40%		11.40%		11.40%
Weighted average remaining lease term	3 years 1 month 6 days		3 years 1 month 6 days		2 years 6 months
Operating cash flows from operating leases			$ 282,209	$ 172,557
Selling, General and Administrative Expenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease expense	$ 140,759	$ 89,717	$ 279,493	$ 211,452
New Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease deposit liability						$ 85,000

SCHEDULE OF PROPERTY AND EQUI_2

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
Cost, beginning balance			$ 29,767
Additions
Disposals
Cost, ending balance	$ 29,767		29,767
Accumulated depreciation, beginning balance			8,261
Depreciation	1,489	$ 1,489	2,977	$ 2,977
Disposals
Accumulated depreciation, ending balance	11,238		11,238
Net book value, beginning balance			21,506
Net book value, ending balance	18,529		18,529
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost, beginning balance			16,839
Additions
Disposals
Cost, ending balance	16,839		16,839
Accumulated depreciation, beginning balance			4,675
Depreciation			1,686
Disposals
Accumulated depreciation, ending balance	6,361		6,361
Net book value, beginning balance			12,164
Net book value, ending balance	10,478		10,478
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost, beginning balance			12,928
Additions
Disposals
Cost, ending balance	12,928		12,928
Accumulated depreciation, beginning balance			3,586
Depreciation			1,291
Disposals
Accumulated depreciation, ending balance	4,877		4,877
Net book value, beginning balance			9,432
Net book value, ending balance	$ 8,051		$ 8,051

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 1,489	$ 1,489	$ 2,977	$ 2,977

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 14, 2023	Nov. 03, 2023	Nov. 03, 2023	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2021
Subsequent Event [Line Items]
Series B preferred shares converted, value						$ 175,294		$ 632,320
Common shares allocate towards conversions					$ 119,285		$ 119,285
Issuance of debt									$ 11,756,563	$ 11,375,690
Subsequent Event [Member]
Subsequent Event [Line Items]
Accrue interest	12%			12%
Subsequent Event [Member] | Subscription Agreements [Member]
Subsequent Event [Line Items]
Issuance of debt	$ 1,250,000			$ 1,250,000
Short term borrowing	$ 1,000,000
Series B Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Series B preferred shares converted, shares			15
Series B preferred shares converted, value			$ 150,000
Accrued dividends		$ 1,063
Common shares allocate towards conversions		$ 202,869
Series B Preferred Stock [Member] | Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Per share		$ 1.71	$ 1.71
Series B Preferred Stock [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Per share		$ 0.80	$ 0.80